[1]
|
Yang, H.I., Lu, S.N., Liaw, Y.F., et al. (2002) Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. New England Journal of Medicine, 347, 168-174. https://doi.org/10.1056/NEJMoa013215
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[3]
|
Cheng, Z., Li, X. and Ding, J. (2016) Characteristics of Liver Cancer Stem Cells and Clinical Correlations. Cancer Letters, 379, 230-238. https://doi.org/10.1016/j.canlet.2015.07.041
|
[4]
|
Gao, Y.-X., Yang, T.-W., Yin, J.-M., et al. (2020) Progress and Prospects of Biomarkers in Primary Liver Cancer (Review). International Journal of Oncology, 57, 54-66. https://doi.org/10.3892/ijo.2020.5035
|
[5]
|
Sugawara, Y. and Hibi, T. (2021) Surgical Treatment of Hepatocellular Carcinoma. BioScience Trends, 15, 138-141.
https://doi.org/10.5582/bst.2021.01094
|
[6]
|
周学平. 原发性肝癌的微转移及其切缘的确定[D]: [博士学位论文]. 上海: 第二军医大学, 2004.
|
[7]
|
Latchana, N., Mcquinn, C., Burkhart, R., Lahey, S. and Pawlik, T.M. (2017) Role of Hepatectomy for Hepatocellular Carcinoma in the Era of Transplantation and Locoregional Therapy. Digestive Disease Interventions, 1, 94-104.
https://doi.org/10.1055/s-0037-1603811
|
[8]
|
El-Seragand, H.B. and Lenhard Rudolph, K. (2007) Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology, 132, 2557-2576. https://doi.org/10.1053/j.gastro.2007.04.061
|
[9]
|
Ruiz-Margáin, A., Román-Calleja, B.M., Moreno-Guillén, P., González-Regueiro, J.A., Kúsulas-Delint, D., Campos-Murguía, A., Flores-García, N.C. and Macías-Rodríguez, R.U. (2021) Nutritional Therapy for Hepatocellular Carcinoma. World Journal of Gastrointestinal Oncology, 13, 1440-1452. https://doi.org/10.4251/wjgo.v13.i10.1440
|
[10]
|
Park, S.H., Lee, S., Song, J.H., et al. (2020) Prognostic Signifi-cance of Body Mass Index and Prognostic Nutritional Index in Stage II/III Gastric Cancer. European Journal of Surgical Oncology, 46, 620-625.
https://doi.org/10.1016/j.ejso.2019.10.024
|
[11]
|
Shimizu, K., Okita, R., Saisho, S., et al. (2015) Preoperative Neu-trophil/Lymphocyte Ratio and Prognostic Nutritional Index Predict Survival in Patients with Non-Small Cell Lung Cancer. World Journal of Surgical Oncology, 13, Article No. 291. https://doi.org/10.1186/s12957-015-0710-7
|
[12]
|
Tokunaga, R., Sakamoto, Y., Nakagawa, S., et al. (2015) Prog-nostic Nutritional Index Predicts Severe Complications, Recurrence, and Poor Prognosis in Patients with Colorectal Can-cer Undergoing Primary Tumor Resection. Diseases of the Colon & Rectum, 58, 1048-1057. https://doi.org/10.1097/DCR.0000000000000458
|
[13]
|
Nagata, S., Maeda, S., Nagamatsu, S., et al. (2021) Prog-nostic Nutritional Index Considering Resection Range Is Useful for Predicting Postoperative Morbidity of Hepatectomy. Journal of Gastrointestinal Surgery, 25, 2788-2795.
https://doi.org/10.1007/s11605-020-04893-z
|
[14]
|
梁荣朴, 叶林森, 张杰滨, 汪国营, 陈规划. 术后预后营养指数在肝细胞癌患者预后中的价值[J]. 中华肝脏外科手术学电子杂志, 2018, 7(2): 138-142.
|
[15]
|
戴青云. 术前预后营养指数(PNI)和中性粒细胞/淋巴细胞比值(NLR)在肝细胞癌术后早期复发中的预测价值[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2019.
|
[16]
|
朱润, 蒋圣军, 隋韬, 李其美. 血液炎症-营养指标在晚期肝癌患者的预后价值研究[J]. 结直肠肛门外科, 2021, 27(S1): 45-46.
|
[17]
|
刘振振. 预后营养指数(PNI)与行根治性切除的肝细胞癌患者预后关系的研究[D]: [硕士学位论文]. 大连: 大连医科大学, 2016.
|
[18]
|
Chan, A.W., Chan, S.L., Wong, G.L., Wong, V.W., Chong, C.C., Lai, P.B., Chan, H.L. and To, K.F. (2015) Prognostic Nutritional Index (PNI) Predicts Tu-mor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma after Surgical Resection. Annals of Surgical Oncol-ogy, 22, 4138-4148. https://doi.org/10.1245/s10434-015-4516-1
|
[19]
|
Okamura, Y., Sugiura, T., Ito, T., Yamamoto, Y., Ashida, R. and Uesaka, K. (2017) The Optimal Cut-Off Value of the Preoperative Prognostic Nutritional Index for the Survival Differs According to the TNM Stage in Hepatocellular Carcinoma. Surgery Today, 47, 986-993. https://doi.org/10.1007/s00595-017-1491-0
|
[20]
|
杨波. 不同肝病患者血清胆碱酯酶与前白蛋白、视黄醇结合蛋白、超敏C-反应蛋白表达水平及其临床意义[J]. 实用医院临床杂志, 2015, 12(6): 73-75, 76.
|
[21]
|
彭秉信, 成海恩, 金亚平, 叶琼瑶. 肝功能损伤患者血清视黄醇结合蛋白的检测[J]. 检验医学与临床, 2012, 9(6): 706-707.
|
[22]
|
姜宇海. 肝脏疾病患者血清中CHE、RBP、TBA、ADA、mAST的变化[J]. 现代预防医学, 2012, 39(24): 6464-6465.
|
[23]
|
陈焕伟, 梁力建, 甄作均. 血清快速转化蛋白测定在肝功能评估中的临床意义[J]. 中华肝胆外科杂志, 2001, 7(7): 403-405.
|
[24]
|
陈小莉, 蔡东联. 视黄醇结合蛋白研究与进展[J]. 肠外与肠内营养, 2000, 7(1): 54-58.
|
[25]
|
顾燕洁, 林炜炜, 王慧. 血清ADA、AFU、RBP和前清蛋白在不同肝病中的诊断价值[J]. 国际检验医学杂志, 2014, 35(9): 1188-1190.
|